Public Profile

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for serious muscle diseases. Founded in 2017, Dyne has quickly established itself in the biopharmaceutical industry, particularly in the realm of gene therapy and muscle-targeted drug development. The company’s core offerings include its proprietary FORCE™ platform, which enables the creation of targeted therapies that address the underlying causes of muscle disorders. This unique approach positions Dyne Therapeutics as a leader in the market, with a commitment to transforming the lives of patients suffering from debilitating conditions. With significant advancements in its research and development pipeline, Dyne Therapeutics continues to make notable strides, solidifying its reputation as a key player in the biotechnology sector.

DitchCarbon Score

How does Dyne Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Dyne Therapeutics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

Let us know if this data was useful to you

Dyne Therapeutics, Inc.'s reported carbon emissions

Dyne Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific climate commitments outlined in their reduction initiatives. As such, there are no reported figures for their carbon emissions, including Scope 1, 2, or 3 emissions. Without defined reduction targets or commitments to industry-standard climate initiatives, it is unclear how the company plans to address its carbon footprint or contribute to climate action. In the absence of specific data, it is essential for stakeholders to monitor Dyne Therapeutics' future disclosures regarding their environmental impact and sustainability efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Dyne Therapeutics, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Dyne Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Dyne Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Biogen

US
Research and development services (73)
Updated 2 days ago

Deciphera Pharmaceuticals

US
Health and social work services (85)
Updated 2 days ago

Stoke Therapeutics, Inc.

US
Health and social work services (85)
Updated 2 days ago

PYC Therapeutics Limited

AU
Health and social work services (85)
Updated 2 days ago

Sarepta Therapeutics

US
Chemicals nec
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers